Table 1 Summary of studies of reprogramming of cancer cells from induce pluripotent stem cell technology. We have modified the summary of the table reported by Camare et al. [25, 26]
From: Cancer cell reprogramming to identify the genes competent for generating liver cancer stem cells
CSCs examples | Original cells | Methods of reprogramming | Karyotype | Chimeras | Teratoma/tumor formation | Drug sensitivity |
|---|---|---|---|---|---|---|
Utikal et al. (2009) [65] | Mice melanoma R454 (rasinduce cells) | Lentivirus OKM | Trisomy chromosomes 8 and 11 | Yes | Yes | No tumor in the absence of Dox |
Carette et al. (2010) [42] | Human leukemia KBM7 (CML) | Retrovirus OSKM | Tetraployd, chromosomes 9 and 22 Ph(+) | Not applied | Yes | Cell type specific drug sensitivity |
Retrovirus OSK (incomplete reprogramming) | ||||||
Miyoshi et al. (2010) [43] | Human gastrointestinal cancer cells | Retrovirus and lentivirus + lipofectamine OSKM | Abnormal | Not applied | Yes | Post iPSC cells—more sensitive to 5-Fu and differentiation inducing drug |
Kuo et al. (2016) [59] | Human HepG2 liver cancer cells and mouse hepatocytes-iPSCs | Lentivirus OSKM + shp53RNA (lentivirus O + c-JUN for direct reprogramming) | Abnormal | Not applied | Yes | Yes |